Form 8-K - Current report:
SEC Accession No. 0001213900-24-078288
Filing Date
2024-09-13
Accepted
2024-09-13 08:30:09
Documents
13
Period of Report
2024-09-09
Items
Item 1.01: Entry into a Material Definitive Agreement

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0214420-8k_citiuspharma.htm   iXBRL 8-K 25419
  Complete submission text file 0001213900-24-078288.txt   198100

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE ctxr-20240909.xsd EX-101.SCH 3009
3 XBRL LABEL FILE ctxr-20240909_lab.xml EX-101.LAB 34240
4 XBRL PRESENTATION FILE ctxr-20240909_pre.xml EX-101.PRE 22355
15 EXTRACTED XBRL INSTANCE DOCUMENT ea0214420-8k_citiuspharma_htm.xml XML 3669
Mailing Address 11 COMMERCE DRIVE 1ST FLOOR CRANFORD NJ 07016
Business Address 11 COMMERCE DRIVE 1ST FLOOR CRANFORD NJ 07016 (908) 967-6676
Citius Pharmaceuticals, Inc. (Filer) CIK: 0001506251 (see all company filings)

EIN.: 273425913 | State of Incorp.: NV | Fiscal Year End: 0930
Type: 8-K | Act: 34 | File No.: 001-38174 | Film No.: 241296506
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)